Abstract
Data supporting a response to treatment with exclusive enteral nutrition in pediatric colonic Crohn’s disease are few. We examined clinical and biochemical responses of ileal, colonic, and ileocolonic Crohn’s disease and assessed the endoscopic and histological colonic mucosal response in the colonic and ileocolonic groups.
We prospectively enrolled 65 children (age: 8–17 years) with acute intestinal Crohn’s disease (Pediatric Crohn’s Disease Activity Index [PCDAI] > 20). After ileocolonoscopy, gastroscopy, and a barium meal and follow-through, they were distributed into three groups (ileal, n = 12, ileocolonic, n = 39; and colonic, n = 14). All patients received exclusive polymeric feed as treatment, with a repeat endoscopy at completion of treatment. At enrollment the ileal group had significantly less severe disease (P = 0.05) compared to the colonic and ileocolonic groups. However, the colonic disease group showed the least fall in PCDAI scores at completion of treatment with enteral nutrition (P = 0.03), with the lowest remission rate (50%, vs 82.1% in the ileocolonic and 91.7% in the ileal group [χ2 test, P = 0.021]). Endoscopic and histologic colonic mucosal assessment showed a posttreatment improvement in the ileocolonic (P ≤ 0.01) but not in the colonic disease group (P = ns). Children with disease in the colon respond better to enteral nutrition if the ileum is also involved. This may be due to different underlying inflammatory mechanisms. Detailed pretreatment assessment in studies of Crohn’s disease according to disease distribution with appropriate individualized tailoring of treatment may be important in this regard.
Similar content being viewed by others
References
Heuschkel RB, Menache CC, Megerian JT, Baird AE: Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr 31(1):8–15, 2000
Cosnes J, Cattan S, Blain A, et al.: Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 8(4):244–250, 2002
Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Buschenfelde KH: T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 44(6):812–818, 1999
Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS: Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 114(5):902–911, 1998
Boot AM, Bouquet J, Krenning EP, Muinck Keizer-Schrama SM: Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 42(2):188–194, 1998
Meister D, Bode J, Shand A, Ghosh S: Anti-inflammatory effects of enteral diet components on Crohn’s disease-affected tissues in vitro. Dig Liver Dis 34(6):430–438, 2002
Sanderson IR, Udeen S, Davies PS, Savage MO, Walker-Smith JA: Remission induced by an elemental diet in small bowel Crohn’s disease. Arch Dis Child 62(2):123–127, 1987
Fell JM, Paintin M, Arnaud-Battandier F, et al.: Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in pediatric Crohn’s disease. Aliment Pharmacol Ther 14(3):281–289, 2000
Beattie RM, Schiffrin EJ, Donnet-Hughes A, et al.: Polymeric nutrition as the primary therapy in children with small bowel Crohn’s disease. Aliment Pharmacol Ther 8(6):609–615, 1994
Afzal NA, Shergill-Bonner R, Fagbemi A, Arnaud-Battandier F, Paintin M, Thomson M, Walker-Smith, JA, Murch S, Heuschkel RB, Fell JM: Clin and mucosal responses to a new casein based enteral feed containing a higher ratio of n-3:n-6 fats and lower level of total saturated fatty acids for treatment of acute Crohn’s disease in children. (abstract) Clin Nutr Supplement 2002, P 204.
Afzal NA, Zaag-Loonen HJ, Arnaud-Battandier F, et al.: Improvement in quality of life of children with acute Crohn’s disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 20(2):167–172, 2004
Williams CB, Nicholls S: Endoscopic features of chronic inflammatory bowel disease in childhood. Baillieres Clin Gastroenterol 8(1):121–131, 1994
Sutton CL, Kim J, Yamane A, et al.: Identification of a novel bacterial sequence associated with Crohn’s disease. Gastroenterology 119(1):23–31, 2000
Breese EJ, Michie CA, Nicholls SW, et al.: Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106(6):1455–1466, 1994
Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A: Supplementary enteral nutrition maintains remission in pediatric Crohn’s disease. Gut 38(4):543–548, 1996
Duerr RH: The genetics of inflammatory bowel disease. Gastroenterol Clin North Am 31(1):63–76, 2002
Dalwadi H, Wei B, Kronenberg M, Sutton CL, Braun J: The Crohn’s diseaseassociated bacterial protein I2 is a novel enteric t cell superantigen. Immunity 15(1):149–158, 2001
Sanderson IR, Boyle S, Williams CB, Walker-Smith JA: Histological abnormalities in biopsies from macroscopically normal colonoscopies. Arch Dis Child 61(3):274–277, 1986
Souza HS, Carvalho AT, Madi K, Silva JR, Elia CS: Phenotypic analysis of intestinal non–inflamed mucosa in Crohn’s disease: evidence of mononuclear cell depletion in lamina propria. Eur J Gastroenterol Hepatol 8(6):563–568, 1996
Freeman HJ: Application of the Vienna Classification for Crohn’s disease to a single clinician database of 877 patients. Can J Gastroenterol 15(2):89–93, 2001
Powell JJ, Harvey RS, Ashwood P, Wolstencroft R, Gershwin ME, Thompson RP: Immune potentiation of ultrafine dietary particles in normal subjects and patients with inflammatory bowel disease. J Autoimmun 14(1):99–105, 2000
D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114(2):262–267, 1998
van den BJ, Kamm MA, Knight SC: Immune sensitization to food, yeast and bacteria in Crohn’s disease. Aliment Pharmacol Ther 15(10):1647–1653, 2001
Andus T, Gross V: Etiology and pathophysiology of inflammatory bowel disease—-environmental factors. Hepatogastroenterology 47(31):29–43, 2000
Ahmad T, Armuzzi A, Bunce M, et al.: The molecular classification of the clinical manifestations of Crohn’s disease. Gastroenterology 122(4):854–866, 2002
Inohara N, Ogura Y, Fontalba A, et al.: Host recognition of bacterial muramyl dipeptide mediated through NOD2, Implications for Crohn’s disease. J Biol Chem 278(8):5509–5512, 2003
Girardin SE, Hugot JP, Sansonetti PJ: Lessons from Nod2 studies: towards a link between Crohn’s disease and bacterial sensing. Trends Immunol 24(12):652–658, 2003
Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK: CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124(4):993–1000, 2003
Keighley MR, Arabi Y, Dimock F, Burdon DW, Allan RN, Alexander-Williams J: Influence of inflammatory bowel disease on intestinal microflora. Gut 19(12):1099–1104, 1978
Rath HC, Ikeda JS, Linde HJ, Scholmerich J, Wilson KH, Sartor RB: Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 116(2):310–319, 1999
Schneider SM, Le Gall P, Girard-Pipau F, et al.: Total artificial nutrition is associated with major changes in the fecal flora. Eur J Nutr 39(6):248–255, 2000
Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM: Assessing activity of pediatric Crohn’s disease: which index to use? Gastroenterology 116(3):527–531, 1999
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Afzal, N.A., Davies, S., Paintin, M. et al. Colonic Crohn’s Disease in Children Does Not Respond Well to Treatment with Enteral Nutrition If the Ileum Is Not Involved. Dig Dis Sci 50, 1471–1475 (2005). https://doi.org/10.1007/s10620-005-2864-6
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-2864-6